Vor Biopharma INC 8-K filings

Vor Biopharma's Chief Financial Officer, Nathan Jorgensen, has resigned, effective June 21, 2024, and the company has appointed interim replacements.

Vor Biopharma's stockholders approved an amendment to their 2021 Equity Incentive Plan, increasing the annual share reserve addition from 4% to 5% and electing two new directors at their annual meeting.

Vor Biopharma has appointed Fouad Namouni, M.D., a seasoned oncology and cancer immunotherapy executive, to its Board of Directors.